# Oncology
Latest news and articles about Oncology
Total: 14 articles found
China’s Biotech Vanguard: Breakthroughs in Lymphoma and Obesity Signal a Shift Toward Global Leadership
China is transitioning from a follower to a leader in biotech, evidenced by Lupin Pharmaceuticals' approval of the first 4th-gen BTK inhibitor and Hansoh Pharma's potent new weight-loss drug. These breakthroughs, supported by massive out-licensing deals with firms like Regeneron, demonstrate that Chinese innovation is now competitive on a global scale.
Illumina’s Genomic Gambit: Standardizing the Search for Cancer’s Ghost Cells
Illumina has launched its first commercial whole-genome sequencing kit for Minimal Residual Disease (MRD) research, aiming to standardize high-sensitivity cancer monitoring. The solution supports both solid and liquid tumors, marking a significant shift from targeted gene panels to comprehensive genomic surveillance in clinical research.
A Thermal Lens on Oncology: The Dawn of Nanoprobe Skin Screening
Scientists in Canada have developed SMEAR-ULM, a smart nanoprobe system that detects early-stage skin cancer by measuring micro-temperature changes on the skin surface. This non-invasive thermal diagnostic tool, published in Nature Sensors, marks a major advancement in early oncological detection.
China’s Oncology Vanguard: Biotech Innovations Take Center Stage at ASCO 2026
Chinese biotech firms and researchers have achieved a record-breaking presence at the 2026 ASCO Annual Meeting, with 95 abstracts selected for major sessions. Led by STAR Market innovators like BeiGene and Biokin, this surge reflects China's transition from a generic-drug manufacturer to a global leader in high-impact oncology research.
mRNA’s New Frontier: MIT Breakthrough Signals an End to ‘Untreatable’ Solid Tumors
Researchers from MIT and MGH have developed a groundbreaking mRNA-based adjuvant that cleared solid tumors in aggressive animal models. By reprogramming dendritic cells to enhance T-cell responses, the study published in Nature Biotechnology offers a potential breakthrough for treating 'cold' tumors that are currently resistant to standard immunotherapy.
China’s Biotech Coming of Age: Hengrui and BMS Strike Record $15.2 Billion Alliance
Hengrui Pharmaceuticals and Bristol Myers Squibb have signed a landmark $15.2 billion strategic partnership to develop 13 early-stage drug candidates. The deal marks a record for Chinese biotech out-licensing and underscores the growing global reliance on Chinese innovation to replenish pharmaceutical pipelines.
The New Vanguard: China’s Biotechs Shift from Mimicry to Mastery at ASCO 2026
China has achieved a record-breaking presence at the 2026 ASCO conference, securing nearly 20% of the world's Late-Breaking Abstracts. This surge reflects a decade-long transition from generic drug manufacturing to leading-edge oncology innovation in fields like ADCs and bispecific antibodies.
Chasing the Holy Grail: HEC Pharm’s Triple Threat at AACR 2026 Signals China’s Oncology Pivot
HEC Pharm presented three innovative oncology candidates at the 2026 AACR meeting, showcasing breakthroughs in Pan-RAS molecular glues, bispecific antibodies, and oral PD-L1 inhibitors. This move highlights the company's strategic pivot toward high-complexity R&D and its ambition to compete in the global precision medicine market.
Eli Lilly Bets $7 Billion on the ‘Holy Grail’ of Cancer Therapy to Diversify Beyond Weight Loss
Eli Lilly is acquiring Kelonia Therapeutics for up to $7 billion to gain access to its revolutionary in-vivo CAR-T technology. This strategic move aims to diversify Lilly's portfolio beyond its successful weight-loss business and establish a leading position in the high-growth oncology market.
Salubris Biotherapeutics Unveils Promising Clinical Data for Novel ADC, Signaling China’s Global Precision Oncology Push
Salubris Biotherapeutics has reported positive Phase 1/2 clinical data for its 5T4-targeting ADC, JK06, at the AACR 2026 conference. The drug shows promising safety and efficacy in treating advanced lung and breast cancers, marking a key advancement in the company's international clinical pipeline.
China’s Nuclear Medicine Leap: Beijing Approves World-First Domestic Radiopharmaceutical
China has approved its first self-developed, world-first radiopharmaceutical, marking a transition from drug imitation to global leadership. This breakthrough in nuclear medicine underscores Beijing's successful integration of biotechnology and nuclear infrastructure.
Precision Oncology Meets Generative AI: Yidu Tech’s Strategic Win at Beijing Cancer Hospital
Yidu Tech has won a 4.88 million RMB bid to implement large language model (LLM) infrastructure at the Peking University Cancer Hospital. This project, funded via a bank-medical partnership, aims to set a new industry benchmark for specialized AI applications in oncology.